Carbonic anhydrase 9 (CA9) (CA9)

Carbonic anhydrase 9 (CA9), frequently referred to as the renal cell carcinoma-associated antigen G250, is a transmembrane zinc metalloenzyme that plays a critical role in the adaptation of tumor cells to hypoxic and acidic environments. It catalyzes the reversible hydration of carbon dioxide into bicarbonate and protons, a process that maintains a favorable intracellular pH for cell survival while acidifying the extracellular microenvironment to promote tumor invasion and metastasis. In clear cell renal cell carcinoma (ccRCC), CA9 is constitutively overexpressed due to the inactivation of the Von Hippel-Lindau (VHL) tumor suppressor gene, which lead to stabilized hypoxia-inducible factors (HIFs) and subsequent transcriptional activation of the CA9 gene. Because its expression is highly specific to malignant tissues and largely absent in most healthy organs (with the exception of the gastrointestinal mucosa), it serves as a premier target for diagnostic imaging and therapeutic interventions. Current strategies include monoclonal antibodies that induce immune-mediated cytotoxicity, small-molecule inhibitors that disrupt pH regulation, and targeted radiopharmaceuticals for both diagnostic staging and radionuclide therapy.

Other names

Renal cell carcinoma-associated antigenG250Antigen G250Carbonic anhydrase IXCAIXCarbonate dehydratase IXMembrane antigen MNP54/58NpMW1

Drugs targeting Carbonic anhydrase 9 (CA9) utilize several distinct mechanisms. Monoclonal antibodies such as girentuximab bind to the extracellular domain of the antigen on the cell surface to trigger antibody-dependent cell-mediated cytotoxicity (ADCC). Small-molecule inhibitors like SLC-0111 target the enzyme's catalytic site to inhibit the conversion of carbon dioxide to bicarbonate and protons, thereby disrupting the pH gradient necessary for tumor survival and chemoresistance. Additionally, CA9-specific ligands are employed in radiopharmaceuticals to deliver radionuclides (such as Lutetium-177 or Zirconium-89) for targeted radionuclide therapy or diagnostic imaging, effectively leveraging the high tumor-specific expression of the antigen.